BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information Letter on Onglyza® (saxagliptin): Risk of serious hypersensitivity reactions and acute pancreatitis

2012.03.08

Active substance: saxagliptin

The pharmaceutical manufacturer issues information on important new findings on the use of Onglyza® (saxagliptin) and the related risk of serious hypersensitivity reactions and acute pancreatitis.

Fachinformation Onglyza® PDF, 167KB, File is accessible

(SPC - available in German only)

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 183KB, File is accessible